These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 19162022)
21. Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1-42. Solórzano-Vargas RS; Vasilevko V; Acero G; Ugen KE; Martinez R; Govezensky T; Vazquez-Ramirez R; Kubli-Garfias C; Cribbs DH; Manoutcharian K; Gevorkian G Mol Immunol; 2008 Feb; 45(4):881-6. PubMed ID: 17889938 [TBL] [Abstract][Full Text] [Related]
22. Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid. Wang MS; Boddapati S; Sierks MR Biotechnol Prog; 2010; 26(4):1172-9. PubMed ID: 20306540 [TBL] [Abstract][Full Text] [Related]
23. Pattern recognition with a fibril-specific antibody fragment reveals the surface variability of natural amyloid fibrils. Haupt C; Bereza M; Kumar ST; Kieninger B; Morgado I; Hortschansky P; Fritz G; Röcken C; Horn U; Fändrich M J Mol Biol; 2011 May; 408(3):529-40. PubMed ID: 21376731 [TBL] [Abstract][Full Text] [Related]
24. Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies. Lindhagen-Persson M; Brännström K; Vestling M; Steinitz M; Olofsson A PLoS One; 2010 Nov; 5(11):e13928. PubMed ID: 21085663 [TBL] [Abstract][Full Text] [Related]
25. Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro. Yoshihara T; Takiguchi S; Kyuno A; Tanaka K; Kuba S; Hashiguchi S; Ito Y; Hashimoto T; Iwatsubo T; Tsuyama S; Nakashima T; Sugimura K J Biochem; 2008 Apr; 143(4):475-86. PubMed ID: 18174189 [TBL] [Abstract][Full Text] [Related]
27. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-aβ antibodies. Sehlin D; Hedlund M; Lord A; Englund H; Gellerfors P; Paulie S; Lannfelt L; Pettersson FE Neurodegener Dis; 2011; 8(3):117-23. PubMed ID: 20714111 [TBL] [Abstract][Full Text] [Related]
28. Structure-based design of conformation- and sequence-specific antibodies against amyloid β. Perchiacca JM; Ladiwala AR; Bhattacharya M; Tessier PM Proc Natl Acad Sci U S A; 2012 Jan; 109(1):84-9. PubMed ID: 22171009 [TBL] [Abstract][Full Text] [Related]
29. Natural human antibodies to amyloid beta peptide. Szabo P; Relkin N; Weksler ME Autoimmun Rev; 2008 Jun; 7(6):415-20. PubMed ID: 18558354 [TBL] [Abstract][Full Text] [Related]
30. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. van Helmond Z; Heesom K; Love S J Neurosci Methods; 2009 Jan; 176(2):206-12. PubMed ID: 18824027 [TBL] [Abstract][Full Text] [Related]
31. Central amyloid-β-specific single chain variable fragment ameliorates Aβ aggregation and neurotoxicity. Nisbet RM; Nigro J; Breheney K; Caine J; Hattarki MK; Nuttall SD Protein Eng Des Sel; 2013 Oct; 26(10):571-80. PubMed ID: 23766374 [TBL] [Abstract][Full Text] [Related]
33. The binding of pullulan modified cholesteryl nanogels to Abeta oligomers and their suppression of cytotoxicity. Boridy S; Takahashi H; Akiyoshi K; Maysinger D Biomaterials; 2009 Oct; 30(29):5583-91. PubMed ID: 19577802 [TBL] [Abstract][Full Text] [Related]
34. Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. Stefani M FEBS J; 2010 Nov; 277(22):4602-13. PubMed ID: 20977664 [TBL] [Abstract][Full Text] [Related]
35. Hybrid peptides attenuate cytotoxicity of beta-amyloid by inhibiting its oligomerization: implication from solvent effects. Sun X; Wu WH; Liu Q; Chen MS; Yu YP; Ma Y; Zhao YF; Li YM Peptides; 2009 Jul; 30(7):1282-7. PubMed ID: 19397942 [TBL] [Abstract][Full Text] [Related]
36. Structures and thermodynamics of Alzheimer's amyloid-beta Abeta(16-35) monomer and dimer by replica exchange molecular dynamics simulations: implication for full-length Abeta fibrillation. Chebaro Y; Mousseau N; Derreumaux P J Phys Chem B; 2009 May; 113(21):7668-75. PubMed ID: 19415895 [TBL] [Abstract][Full Text] [Related]
37. The protective effects and underlying mechanism of an anti-oligomeric Aβ42 single-chain variable fragment antibody. Zhang Y; Chen X; Liu J; Zhang Y Neuropharmacology; 2015 Dec; 99():387-95. PubMed ID: 26256421 [TBL] [Abstract][Full Text] [Related]
38. Synaptic transmission is impaired prior to plaque formation in amyloid precursor protein-overexpressing mice without altering behaviorally-correlated sharp wave-ripple complexes. Hermann D; Both M; Ebert U; Gross G; Schoemaker H; Draguhn A; Wicke K; Nimmrich V Neuroscience; 2009 Sep; 162(4):1081-90. PubMed ID: 19477243 [TBL] [Abstract][Full Text] [Related]
39. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. Bach P; Tschäpe JA; Kopietz F; Braun G; Baade JK; Wiederhold KH; Staufenbiel M; Prinz M; Deller T; Kalinke U; Buchholz CJ; Müller UC J Immunol; 2009 Jun; 182(12):7613-24. PubMed ID: 19494285 [TBL] [Abstract][Full Text] [Related]
40. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. Fändrich M J Mol Biol; 2012 Aug; 421(4-5):427-40. PubMed ID: 22248587 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]